BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day
BioMark Diagnostics Endorses Global Call for Equitable Access to Early Screening on 2026 World Lung Cancer Day Anchored in the 2026 global campaign’s core mission of early detection, equitable access to screening, and compassionate patient support, BioMark advances its multi-marker liquid biopsy to ensure no patient is left behind. VANCOUVER, BRITISH COLUMBIA – (July 31, […]
BioMark’s Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy
BioMark’s Metabolomics Platform Captures Global Scientific Interest Following Publications Demonstrating Superior Diagnostic Performance and Cost Efficiency for Liquid Biopsy Five peer-reviewed studies published in nine months independently confirm high accuracy, robust panel optimization, and commercial viability of BioMark’s blood-based assay. VANCOUVER, BRITISH COLUMBIA – (August 25, 2026) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) […]
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test
BioMark Diagnostics Secures Landmark Canadian and European Patent Allowances for Early-Stage Lung Cancer Blood Test BioMark prepares to launch its breakthrough liquid biopsy powered by a newly patented algorithm validated in over 15,000 samples across Quebec, France, and Germany. VANCOUVER, BRITISH COLUMBIA – (June 23, 2026) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: […]
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform
BioMark Secures Broad U.S. Patent for Urine-Based Lung Cancer Screening, Expanding Differentiated Liquid Biopsy Testing Platform New patent expands globally protected IP estate beyond blood into alternative biofluids, positioning the Company’s clinical mass spectrometry platform against traditional genomic liquid biopsies. VANCOUVER, BRITISH COLUMBIA – (June 9, 2026) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) […]
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum
BioMark Diagnostics to Present Liquid Biopsy Platform at the Canadian Thoracic Society Research Forum BioMark Comprehensive Metabolomics Assay Selected asTop Canadian Innovation for the CTS Beaver Den Innovation Award VANCOUVER, BRITISH COLUMBIA – (April 14, 2026) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid […]
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology
BioMark Diagnostics Announces Publication of Peer-Reviewed Validation of Machine Learning Models for Lung Cancer Detection in Frontiers in Oncology Advancing Superior Accuracy in Early Lung Cancer Detection Using Selective Metabolic Pathways and Data Enrichment for Enhanced Diagnostic Capabilities Vancouver, British Columbia – (January 15, 2026) — BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), […]
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors
BioMark Diagnostics Announces Appointment of Mr. James Lavender to Board of Directors Expanding U.S. market access with an experienced technology investor and AI-driven growth strategist VANCOUVER, BRITISH COLUMBIA – (December 30, 2025) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early […]
BioMark: 2025 Achievements & 2026 Vision
BioMark: 2025 Achievements & 2026 Vision Celebrating A Year of Extraordinary Achievement VANCOUVER, BRITISH COLUMBIA – (December 31, 2025) – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, today issued a Year-End Letter to Shareholders and Team from its […]
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program
BioMark Diagnostics Advances Commercialization Strategy by Initiating ISO 15189 Accreditation Program Company engages Standards Council of Canada; targets ISO 15189 accreditation for early 2026 Vancouver, British Columbia – (December 23, 2025) – BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, is pleased to […]
BioMark Diagnostics Collaborative Lung Cancer Screening Project Honored by ADRIQ during the 35th Innovation Awards Gala
Recognition of BioMark Leadership in Early Cancer Detection Validates Commercialization Trajectory of Multimodal Lung Cancer Screening Platform Vancouver, British Columbia – (December 1st, 2025) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCQB: BMKDF), a leading developer of liquid biopsy technologies for early cancer detection, is honored to announce that the Company and its […]